[A22-57] Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162
Last updated 07.07.2022
Project no.:
A22-57
Commission:
Commission awarded on 25.05.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based chemotherapy at any stage of the disease, when surgery or radiation to cure the cancer is not an option for them
Unchanged after addendum:
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of considerable added benefit
- Patients for whom a treatment option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-162 | Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.